Fuzhong Peng

Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

A. Hui, Ö. Türeci, U. Şahin, 2022, The Lancet Regional Health - Western Pacific.

First report demonstrating the safety and immunogenicity of the SARS-COV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, observer-blind Phase I study

A. Hui, Ö. Türeci, U. Şahin, 2021 .

Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial

A. Hui, Ö. Türeci, U. Şahin, 2022, Advances in Therapy.

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study

A. Hui, Ö. Türeci, U. Şahin, 2021, Nature Medicine.